JNPR
59
3
MKC
54
3
KSS
36
2
JNJ
30
4
XYL
29
4
CVX
25
14
NSC
33
6
MMM
35
3
GE
60
5
LRCX
56
4
STZ
42
2
EBAY
42
2
MAC
53
5
BLK
46
2
RF
44
10
VMC
41
2
FIS
43
5
ABBV
40
5
KIM
58
2
JBHT
46
4
JNPR
59
3
MKC
54
3
KSS
36
2
JNJ
30
4
XYL
29
4
CVX
25
14
NSC
33
6
MMM
35
3
GE
60
5
LRCX
56
4
STZ
42
2
EBAY
42
2
MAC
53
5
BLK
46
2
RF
44
10
VMC
41
2
FIS
43
5
ABBV
40
5
KIM
58
2
JBHT
46
4
Financhill
Back

NanoVibronix 10K Form

Sell
23

NAOV
NanoVibronix

Last Price:
$0.58
Seasonality Move:
-3.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NAOV News And Ratings

See the #1 stock for the next 7 days that we like better than NAOV

NAOV Financial Statistics

Sales & Book Value

Annual Sales: $2.3M
Cash Flow: $-836K
Price / Cash Flow: 0
Annual Sales: $0.67
Price / Book: 1.16

Profitability

EPS (TTM): -1.23000
Net Income (TTM): $-3.1M
Gross Margin: $1.5M
Return on Equity: -91.36%
Return on Assets: -50.36%

NanoVibronix Earnings Forecast

Key NanoVibronix Financial Ratios

  • The Gross Profit Margin over the past 13 years for NAOV is 67.32%.
  • The Selling, General & Administrative Expenses for NAOV have been equal to 209.72% of Gross Profit Margin.
  • The Research & Development expenses have been 8.10% of Revenue.
  • The Interest Expense is -3.64% of Operating Income.
  • The Net Earning history of NAOV is -162.55% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 7 years.

NanoVibronix Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: NAOV
CUSIP: 63008J
Website: nanovibronix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.74
Quick Ratio: 0.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NAOV Technical Analysis vs Fundamental Analysis

Sell
23
NanoVibronix (NAOV) is a Sell

Is NanoVibronix a Buy or a Sell?

  • NanoVibronix stock is rated a Sell
    The current NanoVibronix [NAOV] share price is $0.58. The Score for NAOV is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.